Progress pre-clinical development of compounds for leishmaniasis
current phase of drug development
updated 1 Jun 2021
In April 2017, DNDi and GSK entered into an agreement for the pre-clinical development of two compounds for leishmaniasis that were developed through a collaboration between the GSK Global Health Unit and the Drug Discovery Unit at the University of Dundee, with co-funding support from Wellcome.
News & press releases
Get our latest news, personal stories, research articles, and job opportunities.